These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 2120204

  • 1. New pharmacologic approaches to obsessive compulsive disorder.
    Insel TR.
    J Clin Psychiatry; 1990 Oct; 51 Suppl():47-51; discussion 56-8. PubMed ID: 2120204
    [Abstract] [Full Text] [Related]

  • 2. Management of treatment-refractory obsessive compulsive disorder patients.
    Dominguez RA, Mestre SM.
    J Clin Psychiatry; 1994 Oct; 55 Suppl():86-92. PubMed ID: 7961537
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
    Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J.
    Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
    [Abstract] [Full Text] [Related]

  • 5. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
    Zohar J, Insel TR.
    Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M, Pini S, Bellantuono C, Wilkinson G.
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA, Seay SM.
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Biological treatments in obsessive-compulsive disorder].
    Montgomery SA, Fineberg NA, Montgomery D.
    Encephale; 1990 Feb; 16 Spec No():335-9. PubMed ID: 2209492
    [Abstract] [Full Text] [Related]

  • 12. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ, Goodman WK, Price LH.
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacotherapy of obsessive compulsive disorder.
    Goodman WK, McDougle CJ, Price LH.
    J Clin Psychiatry; 1992 Apr; 53 Suppl():29-37. PubMed ID: 1532962
    [Abstract] [Full Text] [Related]

  • 15. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
    Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF.
    J Clin Psychiatry; 1990 Mar; 51(3):119-23. PubMed ID: 2106515
    [Abstract] [Full Text] [Related]

  • 16. Neurobiology of obsessive compulsive disorder: a possible role for serotonin.
    Winslow JT, Insel TR.
    J Clin Psychiatry; 1990 Aug; 51 Suppl():27-31; discussion 55-8. PubMed ID: 2199432
    [Abstract] [Full Text] [Related]

  • 17. Fluvoxamine as an antiobsessional agent.
    Goodman WK, Price LH, Rasmussen SA, Heninger GR, Charney DS.
    Psychopharmacol Bull; 1989 Aug; 25(1):31-5. PubMed ID: 2505302
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.